Community perspectives on treating asymptomatic infections for malaria elimination in The Gambia.
Adolescent
Adult
Antimalarials
/ administration & dosage
Artemisinins
/ administration & dosage
Asymptomatic Infections
Child
Child, Preschool
Cross-Sectional Studies
Disease Eradication
Female
Gambia
Humans
Infant
Infant, Newborn
Malaria
/ drug therapy
Male
Patient Acceptance of Health Care
Quinolines
/ administration & dosage
Young Adult
Asymptomatic infection
Community perspectives
Elimination
Malaria
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
18 Feb 2019
18 Feb 2019
Historique:
received:
24
10
2018
accepted:
10
02
2019
entrez:
20
2
2019
pubmed:
20
2
2019
medline:
19
3
2019
Statut:
epublish
Résumé
Innovative and cost-effective strategies that clear asymptomatic malaria infections are required to reach malaria elimination goals, but remain a challenge. This mixed methods study explored people's attitudes towards the reactive treatment of compound contacts of malaria cases with a 3-day course of dihydroartemisinin-piperaquine (DHAP), the socio-cultural representations of asymptomatic infections, and more specifically their treatment. Prior to the start of the intervention, a sequential mixed method study was carried out. Qualitative data collection involved in-depth interviews and participant observations (including informal conversations) with key informants from the trial communities and the trial staff. Quantitative data were derived from a pre-trial cross-sectional survey on health literacy and health-seeking behaviour among randomly selected members of the study communities. In the pre-trial cross-sectional survey, 73% of respondents reported that malaria could be hidden in the body without symptoms. Whilst this may be interpreted as people's comprehension of asymptomatic malaria, qualitative data indicated that informants had different interpretations of asymptomatic disease than the biomedical model. It was described as: (i) a minor illness that does not prevent people carrying out daily activities; (ii) an illness that oscillates between symptomatic and asymptomatic phases; and, (iii) a condition where disease agents are present in the body but remain hidden, without signs and symptoms, until something triggers their manifestation. Furthermore, this form of hidden malaria was reported to be most present in those living in the same compound with a malaria case (71%). Treating asymptomatic malaria with pharmaceuticals was considered acceptable. However, people felt uncertain to take treatment without screening for malaria first, largely due to the lack of symptoms. Knowledge of asymptomatic malaria was not a strong re-inforcement for treatment adherence. In this study, the pre-intervention active engagement of communities existed of having people co-design accurate information messages about their personal risk of malaria, which increased their trust in expert knowledge and thus proved essential for the successful implementation of the community-based intervention.
Sections du résumé
BACKGROUND
BACKGROUND
Innovative and cost-effective strategies that clear asymptomatic malaria infections are required to reach malaria elimination goals, but remain a challenge. This mixed methods study explored people's attitudes towards the reactive treatment of compound contacts of malaria cases with a 3-day course of dihydroartemisinin-piperaquine (DHAP), the socio-cultural representations of asymptomatic infections, and more specifically their treatment.
METHODS
METHODS
Prior to the start of the intervention, a sequential mixed method study was carried out. Qualitative data collection involved in-depth interviews and participant observations (including informal conversations) with key informants from the trial communities and the trial staff. Quantitative data were derived from a pre-trial cross-sectional survey on health literacy and health-seeking behaviour among randomly selected members of the study communities.
RESULTS
RESULTS
In the pre-trial cross-sectional survey, 73% of respondents reported that malaria could be hidden in the body without symptoms. Whilst this may be interpreted as people's comprehension of asymptomatic malaria, qualitative data indicated that informants had different interpretations of asymptomatic disease than the biomedical model. It was described as: (i) a minor illness that does not prevent people carrying out daily activities; (ii) an illness that oscillates between symptomatic and asymptomatic phases; and, (iii) a condition where disease agents are present in the body but remain hidden, without signs and symptoms, until something triggers their manifestation. Furthermore, this form of hidden malaria was reported to be most present in those living in the same compound with a malaria case (71%).
CONCLUSION
CONCLUSIONS
Treating asymptomatic malaria with pharmaceuticals was considered acceptable. However, people felt uncertain to take treatment without screening for malaria first, largely due to the lack of symptoms. Knowledge of asymptomatic malaria was not a strong re-inforcement for treatment adherence. In this study, the pre-intervention active engagement of communities existed of having people co-design accurate information messages about their personal risk of malaria, which increased their trust in expert knowledge and thus proved essential for the successful implementation of the community-based intervention.
Identifiants
pubmed: 30777112
doi: 10.1186/s12936-019-2672-7
pii: 10.1186/s12936-019-2672-7
pmc: PMC6378745
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Quinolines
0
artenimol
6A9O50735X
piperaquine
A0HV2Q956Y
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Subventions
Organisme : Medical Research Council
ID : MC_EX_MR/N006100/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K012126/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Références
Parasitol Today. 1994 Nov;10(11):439-42
pubmed: 15275531
Health Policy Plan. 2006 Sep;21(5):373-91
pubmed: 16940303
J Health Commun. 2009 Jun;14(4):384-99
pubmed: 19466649
Malar J. 2010 Jan 22;9:30
pubmed: 20096111
PLoS One. 2010 Aug 18;5(8):e12242
pubmed: 20805878
Lancet. 2010 Nov 6;376(9752):1592-603
pubmed: 21035841
Malar J. 2011 Aug 04;10:225
pubmed: 21816085
Malar J. 2012 Jan 31;11:29
pubmed: 22289302
Malar J. 2012 Jun 08;11:185
pubmed: 22681850
Mediterr J Hematol Infect Dis. 2012;4(1):e2012036
pubmed: 22708051
PLoS One. 2013 May 20;8(5):e63830
pubmed: 23700437
PLoS Med. 2013;10(6):e1001467
pubmed: 23853551
PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2410
pubmed: 24069473
Front Immunol. 2014 Jun 11;5:280
pubmed: 24966859
Nat Rev Microbiol. 2014 Dec;12(12):833-40
pubmed: 25329408
Malar J. 2015 Apr 24;14:167
pubmed: 25908392
Am J Trop Med Hyg. 2015 Jul;93(1):125-34
pubmed: 26013371
Malar J. 2015 Aug 14;14:314
pubmed: 26268225
Malar J. 2015 Oct 16;14:410
pubmed: 26474852
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14688-93
pubmed: 26553981
Malar J. 2015 Dec 02;14:491
pubmed: 26630884
PLoS Med. 2016 Jan 19;13(1):e1001942
pubmed: 26783752
Malar J. 2016 Feb 06;15:71
pubmed: 26852227
Anthropol Med. 1998 Apr;5(1):43-61
pubmed: 26868738
Anthropol Med. 1998 Apr;5(1):63-79
pubmed: 26868739
Malar J. 2016 Mar 02;15:136
pubmed: 26935955
Malar J. 2016 Jun 22;15:333
pubmed: 27333893
Malar J. 2016 Sep 27;15(1):494
pubmed: 27677694
Malar J. 2016 Nov 2;15(1):523
pubmed: 27806717
Wellcome Open Res. 2017 Jul 28;2:59
pubmed: 28894847
Glob Health Action. 2017;10(1):1366136
pubmed: 28914184
Malar J. 2018 Jan 9;17(1):15
pubmed: 29316932
Lancet Infect Dis. 2018 May;18(5):565-572
pubmed: 29398388
Trials. 2018 Feb 20;19(1):126
pubmed: 29463288
PLoS One. 2018 Apr 12;13(4):e0195809
pubmed: 29649317
PLoS Pathog. 2018 May 3;14(5):e1006965
pubmed: 29723307
Lancet Infect Dis. 2018 Oct;18(10):1108-1116
pubmed: 30170986
PLoS One. 2018 Dec 11;13(12):e0208912
pubmed: 30533024
Soc Sci Med. 1995 May;40(9):1271-7
pubmed: 7610432
J Ethnopharmacol. 1995 Nov 3;48(3):119-30
pubmed: 8719973